There are currently 447 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - North Kansas City Hospital, Kansas City, Missouri +1 locations
Conditions: Breast Cancer
Register for Updates
Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction
NCT05049070
Recruiting
This study evaluates the reliability, validity and safety of a self administered, subjective refraction test via a mobile medical app (GoEyes) as compared to standard of care subjective manifest refraction performed by a health care provider, in subjects who have no known ocular disease or condition other than refractive error.
Gender:
All
Ages:
Between 18 years and 39 years
Trial Updated:
04/04/2023
Locations: Tauber Eye Center, Kansas City, Missouri
Conditions: Refractive Errors
Register for Updates
An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers
NCT03882359
Recruiting
Definity (perflutren lipid microspheres, Lantheus Medical Imaging) is an ultrasound contrast indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. MVT-100 (the investigational pharmaceutical) is similar to Definity, with the exception of the removal of one lipid in the lipid blend and substitution of another lipid. This study is intended to evaluate the safety and efficacy o... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
03/30/2023
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Heart Diseases
Register for Updates
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
NCT00574327
Recruiting
The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of GERD and BE patients and risk factors for development of BE in patients with chronic GERD and progression of BE to dysplasia and adenocarcinoma will provide useful information to develop a decision mod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2023
Locations: Department of Veterans Affairs Medical Center, Kansas City, Missouri
Conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
Register for Updates
MyLeukoMAP™ Genomic Survival Prediction Assay Pivotal Clinical Study
NCT05258942
Recruiting
The MyLeukoMAP™ Pivotal Clinical Study will assess the accuracy of MyLeukoMAP™, a new molecular blood test, performed within 30 days before scheduled surgical / interventional therapies for Heart Failure, to determine its effectiveness in improving clinical decision support by providing a quantitative prediction of low, indeterminate, or high risk of death one year after surgical / interventional therapies that is not identified by current diagnostic tools.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Heart Failure
Register for Updates
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)
NCT05570448
Recruiting
This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months. Patients must have a positive pH test and a negative manometry (no treatment) procedure.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/05/2022
Locations: Kansas City VA Hospital, Kansas City, Missouri
Conditions: Gastro Esophageal Reflux
Register for Updates
Rib Fixation for Clinically Severe Rib Fractures From Trauma
NCT02595593
Recruiting
This is a multicenter randomized study investigating the differences in clinical outcomes of patients between two standard of care pathways for rib trauma: patients who receive rib fixation versus patients who receive modern critical care and pain control after sustaining clinically significant rib fractures from trauma.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/07/2022
Locations: Research Medical Center, Kansas City, Missouri
Conditions: Rib Fracture, Flail Chest
Register for Updates
Linking Novel Diagnostics With Data-Driven Clinical Decision Support in the Emergency Department
NCT05335135
Recruiting
The primary objective of this study is to validate the use of an electronic clinical decision support (CDS) tool, TriageGO with Monocyte Distribution Width (TriageGO-MDW), in the emergency department (ED). TriageGO-MDW is non-device CDS designed to support emergency clinicians (nurses, physicians and advanced practice providers) in performing risk-based assessment and prioritization of patients during their ED visit. This study will follow an effectiveness-implementation hybrid design via the fo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2022
Locations: University Health Truman Medical Center, Kansas City, Missouri
Conditions: Inpatient Hospitalization, Intensive Care Unit Admission, Inpatient Mortality, Sepsis and Septic Shock
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Kansas City VA Medical Center, Kansas City, Missouri
Conditions: End Stage Liver Disease
Register for Updates
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
NCT04939116
Recruiting
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: Clinical Research Consultants, LLC., Kansas City, Missouri
Conditions: Glomerular Disease, Proteinuria
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Mid America Heart Institute, Kansas City, Missouri
Conditions: Coronary Artery Disease
Register for Updates
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
NCT05025735
Recruiting
This will be a single arm, open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC. The objective of this study is to determine if the addition of dapagliflozin to the combination of alpelisib and fulvestrant leads to significant reduction in all-grade hyperglycemia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Saint Luke's Cancer Institute, Kansas City, Missouri
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Register for Updates